Abstract

Idiopathic inflammatory myopathies are a group of rare autoimmune diseases. A subset of these cases may occur in association with an underlying malignancy, a condition known as cancer-associated myositis (CAM), reported in approximately 13% of cases according to the Euromyositis registry. The malignancies most commonly linked to this syndrome include cancers of the lung, thyroid, breast, stomach, ovaries, cervix, and hepatocellular carcinoma. However, the association with endometrial adenocarcinoma has been only rarely described in the medical literature. In our review, we identified six previously reported cases (from Japan, Canada, and the United States). We present the first documented case in Latin America of a patient who developed this uncommon form of CAM, characterized by severe clinical presentation and favorable response following treatment directed at the neoplasm and administration of intravenous immunoglobulin.

Keywords

  • LQAS
  • method Coverage
  • Chemoprevention
  • Seasonal
  • Malaria

References

  1. Lilleker, J.B.; Vencovsky, J.; Wang, G. The EuroMyositis registry: An international collaborative tool to facilitate myositis research. Ann. Rheum. Dis. 2018, 77, 30–39.Baig S, Paik JJ. Inflammatory muscle disease – An update. Best Pract Res Clin Rheumatol. febrero de 2020;34(1):101484.
  2. Leclair, Valériea,b,c; Notarnicola, Antonellad; Vencovsky, Jirie. Polymyositis: does it really exist as a distinct clinical subset?. Current Opinion in Rheumatology 33(6):p 537-543, November 2021. | DOI: 10.1097/BOR.0000000000000837
  3. Ceribelli A, Tonutti A, Isailovic N. Established and novel insights to guide cancer assessment in patients with idiopathic inflammatory myopathies. Semin Arthritis Rheum. 2025 Apr;71:152619. doi: 10.1016/j.semarthrit.2024.152619. Epub 2024 Dec 22. PMID: 39798246.
  4. Hsu JL, Liao MF, Chu CC. Reappraisal of the incidence, various types and risk factors of malignancies in patients with dermatomyositis and polymyositis in Taiwan. Sci Rep. 25 de febrero de 2021;11(1):4545.
  5. Chang, Lili MMa,d; Zhang, Lina MDb; Jia, Haiquan MMc. Malignancy in dermatomyositis: A retrospective paired case–control study of 202 patients from Central China. Medicine 99(34):p e21733, August 21, 2020. | DOI: 10.1097/MD.0000000000021733
  6. Marzęcka M, Niemczyk A, Rudnicka L. Autoantibody Markers of Increased Risk of Malignancy in Patients with Dermatomyositis. Clin Rev Allergy Immunol. 2022;63(2):289-96.
  7. Khamooshi P, Pavon MR, Kang-Yoonsun C. A Rare Case of Paraneoplastic Dermatomyositis in a Patient With Metastatic Endometrial Cancer. Ann Intern Med Clin Cases. 2022;1(9):e220480.
  8. Lim D, Landon-Cardinal O, Belisle A. A case of dermatomyositis with anti-TIF1γ antibodies revealing isolated para-aortic lymphadenopathy metastatic recurrence of endometrial cancer: A case report. SAGE Open Med Case Rep. 2020 Oct 10;8:2050313X20961977. doi: 10.1177/2050313X20961977.
  9. Wada C, Hua CN, Carney ME. Paraneoplastic syndrome in Hawai'i: a case of dermatomyositis associated with endometrial cancer. Hawaii J Med Public Health. 2014 Apr;73(4):112-4. PMID: 24765559; PMCID: PMC3998229.
  10. Kasuya, A., Hamaguchi, Y., Fujimoto, M. TIF1γ-overexpressing, highly progressive endometrial carcinoma in a patient with dermato-myositis positive for malignancy-associated anti-p155/140 autoantibody. Acta Dermato-Venereologica, 2013. 93(6), 715–716. https://doi.org/10.2340/00015555-1550
  11. Famularo G. Amyopathic dermatomyositis associated with an endometrial adenocarcinoma. Our Dermatol Online. 2017;8(2):235-236.
  12. Verducci MA, Malkasian GD Jr, Friedman SJ, Winkelmann RK. Gynecologic carcinoma associated with dermatomyositis-polymyositis. Obstet Gynecol. 1984 Nov;64(5):695-8. PMID: 6493661.
  13. Yang H, Peng Q, Yin L. Identification of multiple cancer-associated myositis-specific autoantibodies in idiopathic inflammatory myopathies: a large longitudinal cohort study. Arthritis Res Ther. diciembre de 2017;19(1):259.
  14. Lauinger J, Ghoreschi K, Volc S. Characteristics of dermatomyositis patients with and without associated malignancy. JDDG J Dtsch Dermatol Ges. 2021;19(11):1601-11.
  15. Chang L, Zhang L, Jia H. Malignancy in dermatomyositis. Medicine (Baltimore). 21 de agosto de 2020;99(34):e21733.
  16. Cho HG, Kuo KY, Xiao K. Azathioprine and risk of multiple keratinocyte cancers. J Am Acad Dermatol. enero de 2018;78(1):27-28.e1.
  17. Ytterberg SR, Bhatt DL, Mikuls TR. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N Engl J Med. 27 de enero de 2022;386(4):316-26.
  18. András C, Bodoki L, Nagy-Vincze M. Retrospective Analysis of Cancer-Associated Myositis Patients over the Past 3 Decades in a Hungarian Myositis Cohort. Pathol Oncol Res. 2020;26(3):1749-55.
  19. Meyer A, Scirè CA, Talarico R. Idiopathic inflammatory myopathies: state of the art on clinical practice guidelines. RMD Open. febrero de 2019;4(Suppl 1):e000784.
  20. Oldroyd AGS, Allard AB, Callen JP. A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies. Rheumatology. 18 de junio de 2021;60(6):2615-28.
  21. Motomura K, Yamashita H, Yamada S. Clinical characteristics and prognosis of polymyositis and dermatomyositis associated with malignancy: a 25-year retrospective study. Rheumatol Int. octubre de 2019;39(10):1733-9.